Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability

The Journal of Pharmacology and Experimental Therapeutics
Todd WisialowskiA A Fossa

Abstract

Antibacterial drugs are known to have varying degrees of cardiovascular liability associated with QT prolongation that can lead to the ventricular arrhythmia torsade de pointes. The purpose of these studies was to compare the assessment for the arrhythmogenic risk of moxifloxacin, erythromycin, and telithromycin. Each drug caused dose-dependent inhibition of the rapidly activating delayed rectifier potassium current encoded by the human ether-á-go-go-related gene (hERG) with IC20 concentrations of 31 microM (moxifloxacin), 21 microM (erythromycin), and 11 microM (telithromycin). These drugs were also evaluated in an anesthetized guinea pig model to measure changes in monophasic action potential duration (MAPD) and to quantify beat-to-beat alternations in MAPD during rapid ventricular pacing. Moxifloxacin dose dependently increased MAPD and caused a rate-dependent increase in alternans at the highest achieved free drug concentration (41 microM). Erythromycin also increased MAPD at its highest free drug concentration (58 microM), but alternans occurred at a relatively lower therapeutic multiple (13.9 microM), and the magnitude of alternans at higher concentrations was independent of pacing rate. Further analysis of the data showe...Continue Reading

References

Dec 1, 1996·Journal of the American College of Cardiology·C AntzelevitchG X Yan
Mar 17, 1999·Circulation·J M PastoreD S Rosenbaum
Jun 18, 2002·The Journal of Pharmacology and Experimental Therapeutics·Walter A VolbergJun Zhou
Nov 8, 2002·American Heart Journal·Mark E AndersonUNKNOWN Duke Clinical Research Institute/American Heart Journal Expert Meeting on Repolarization Changes
Mar 7, 2003·Clinical Pharmacology and Therapeutics·Jean-Louis DémolisChristian Funck-Brentano
Aug 2, 2003·Critical Reviews in Clinical Laboratory Sciences·William T Clusin
Aug 5, 2003·Journal of Applied Physiology·Bruce D Nearing, Richard L Verrier
Feb 21, 2004·European Journal of Pharmacology·Katsuyoshi ChibaKeitaro Hashimoto
Feb 21, 2004·European Journal of Pharmacology·Anthony A FossaBernard Fermini
Apr 20, 2004·Journal of Cardiovascular Electrophysiology·Robert R FenichelUNKNOWN Independent Academic Task Force
Sep 10, 2004·The New England Journal of Medicine·Wayne A RayC Michael Stein
Jan 8, 2005·European Heart Journal·M L De BruinH G M Leufkens
Feb 5, 2005·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Rashmi R Shah
Apr 27, 2005·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Sanjiv M NarayanMichael E Cain
Jun 7, 2005·Journal of Pharmacological and Toxicological Methods·H van der LindeD J Gallacher
Jun 14, 2005·Current Opinion in Chemical Biology·Glenn A ReinhartGary A Gintant
Jun 25, 2005·Journal of Pharmacological and Toxicological Methods·Chris L LawrenceJean-Pierre Valentin
Jun 25, 2005·Journal of Pharmacological and Toxicological Methods·Gregory S FriedrichsAlan Bass
Jul 19, 2005·British Journal of Pharmacology·Sotiria Bexis, James R Docherty

❮ Previous
Next ❯

Citations

Apr 24, 2013·Cancer Chemotherapy and Pharmacology·Daryl SonnichsenFrank G Haluska
Jun 18, 2010·Journal of Cardiovascular Pharmacology·Richard L Verrier, Tuomo Nieminen
Feb 13, 2010·Pharmacogenetics and Genomics·Connie OshiroRuss B Altman
Nov 26, 2010·Journal of Neurogastroenterology and Motility·Jean M LarsonBaharak Moshiree
Dec 17, 2008·British Journal of Clinical Pharmacology·Emanuel RaschiFabrizio De Ponti
Jun 16, 2010·Journal of Clinical Pharmacology·Yeong-Liang LinMei-Fen Kung
Jan 17, 2014·Cardiovascular Therapeutics·Elsayed Abo-SalemKenneth Nugent
Aug 26, 2009·British Journal of Pharmacology·Joffrey DucroqM Le Grand
Aug 4, 2012·Current Opinion in Pharmacology·Gareth J Sanger
Feb 7, 2017·Antibiotics·Jay W Mason, Thomas E Moon
Aug 29, 2014·Therapeutic Advances in Infectious Disease·Jules C HancoxAdrian Baranchuk
Jun 8, 2013·Current Protocols in Pharmacology·Claire Townsend, Barry S Brown
Jun 22, 2016·Antimicrobial Agents and Chemotherapy·S Ken Tanaka, Stephen Villano
Sep 6, 2007·The Journal of Toxicological Sciences·Kazuya KimuraHisanori Takanashi
Jul 15, 2016·Journal of Complementary & Integrative Medicine·Mirian Nnemdi AshibuogwuOlaoluwa Sesan Olukiran
May 8, 2009·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Françoise Van Bambeke, Paul M Tulkens

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.